查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1599235

靜脈血栓栓塞症治療藥物市場：依藥物類別、器材、應用、最終用途 - 全球預測 2025-2030

Venous Thromboembolism Therapeutic Market by Drug Class (Direct Thrombin Inhibitors, Factor XA Inhibitors, Heparin), Device (Compression System, IVC Filters, Stockings), Application, End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

靜脈血栓栓塞症治療市場2023年估值為24億美元，預計2024年將達25.4億美元，複合年成長率為5.84%，預計到2030年將達到35.7億美元。

靜脈血栓栓塞症(VTE) 醫學包括專門針對靜脈內血栓的治療和預防措施，例如深層靜脈栓塞症(DVT) 和肺動脈栓塞(PE)。 VTE 藥物市場主要是由於生活方式的改變、肥胖症的增加和人口老化而導致這些疾病的發生率不斷增加。由於其潛在的危及生命的性質，對有效 VTE 管理的需求是顯而易見的，這進一步增加了醫療機構的關鍵需求。治療藥物用途廣泛，包括抗凝血劑、血栓溶解劑和機械方法，主要最終使用者為醫院、專科診所和門診醫療機構。直介面服抗凝血劑 (DOAC) 等近期創新技術因其比傳統Warfarin療法更高的安全性和易用性而不斷增加，帶來了利潤豐厚的市場機會。此外，人們對基因療法和個人化醫療等新型療法的認知不斷提高，並取得了進步，為進一步成長提供了前景。然而，成長受到嚴格監管要求、高昂治療成本以及與領先治療方法相關的潛在副作用等限制因素的挑戰。競爭方面，大藥專利到期後學名藥廠商的進入也是價格方面的一大問題。創新的最佳途徑在於開發更安全、更有效、副作用更少的治療方法，並應用人工智慧來預測患者特定的治療反應。此外，研究 VTE 的遺傳基礎以開發標靶治療可能會促進未來的成長。為公司提供的策略建議包括投資創新療法的研發、擴大病患教育計畫以加強早期檢測和預防，以及建立策略聯盟以提高市場滲透率。 VTE 治療市場是動態的，其特點是不斷發展的技術和標準，反映了該醫療保健行業的複雜性和潛力。

主要市場統計
基準年[2023] 24億美元
預測年份 [2024] 25.4億美元
預測年份 [2030] 35.7億美元
複合年成長率（%） 5.84%

市場動態：快速發展的靜脈血栓栓塞症藥物市場的關鍵市場洞察

供需的動態交互作用正在改變靜脈血栓栓塞症藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 靜脈血栓栓塞症的發生率增加
    • 髖關節和關節重建置換術等外科手術的增加
    • 提高患者對 VTE 治療的認知
  • 市場限制因素
    • 與 VTE 藥物相關的高治療成本和副作用
  • 市場機會
    • 開發高效率、先進的技術
    • 政府針對靜脈血栓栓塞症治療的舉措
  • 市場挑戰
    • 嚴格而複雜的監管程序

波特五力：駕馭靜脈血栓栓塞症藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解外部對靜脈血栓栓塞症藥物市場的影響

外部宏觀環境因素在塑造靜脈血栓栓塞症治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解靜脈血栓栓塞症治療藥物市場的競爭狀況

靜脈血栓栓塞症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣靜脈血栓栓塞症治療市場供應商的績效評估

FPNV定位矩陣是評估靜脈血栓栓塞症治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪靜脈血栓栓塞症治療藥物市場的成功之路

對靜脈血栓栓塞症治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 靜脈血栓栓塞症的發生率增加
      • 髖關節和膝關節置換手術等外科手術的增加
      • 提高患者對 VTE 治療的認知
    • 抑制因素
      • VTE 治療藥物相關的高治療成本和副作用
    • 機會
      • 開發高效率、先進的技術
      • 政府關於靜脈血栓栓塞症治療的舉措
    • 任務
      • 嚴格而複雜的監管程序
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章靜脈血栓栓塞症治療藥物市場（依藥物類別）

  • 直接凝血酶抑制劑
  • XA因子抑制劑
  • 肝素
  • 維生素K拮抗劑

第7章靜脈血栓栓塞症治療藥物市場：依設備分類

  • 壓縮系統
  • 下腔靜脈過濾器
  • 絲襪
  • 血栓清除系統

第8章靜脈血栓栓塞症治療藥物市場：依應用分類

  • 深層靜脈栓塞症
  • 肺動脈栓塞

第9章靜脈血栓栓塞症治療藥物市場：依最終用途分類

  • 導管實驗室
  • 醫院

第10章 北美及南美靜脈血栓栓塞症藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太靜脈靜脈血栓栓塞症藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲靜脈靜脈血栓栓塞症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AngioDynamics, Inc.
  • Argon Medical Devices, Inc.
  • Arjo AB
  • Bio Compression Systems
  • BioInvent International AB
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Cardinal Health, Inc.
  • Cook Group Incorporated
  • DAIICHI SANKYO COMPANY, LIMITED
  • eXIthera Pharmaceuticals
  • Koninklijke Philips NV
  • Medtronic PLC
  • Sanofi SA
Product Code: MRR-034B50030388

The Venous Thromboembolism Therapeutic Market was valued at USD 2.40 billion in 2023, expected to reach USD 2.54 billion in 2024, and is projected to grow at a CAGR of 5.84%, to USD 3.57 billion by 2030.

Venous Thromboembolism (VTE) Therapeutics encompass treatments and preventative measures for managing blood clots in the vein, notably types like deep vein thrombosis (DVT) and pulmonary embolism (PE). The market for VTE therapeutics is driven by the rising incidence of these conditions due largely to lifestyle changes, increasing cases of obesity, and a growing aging population. The necessity of effective VTE management is evident in its potential life-threatening nature, compounding its critical demand in healthcare settings. Therapeutics applications span across anticoagulants, thrombolytics, and mechanical methods, with hospitals, specialized clinics, and outpatient healthcare facilities being the principal end-users. Recent innovations such as direct oral anticoagulants (DOACs) are increasing due to their enhanced safety profile and ease of use over traditional warfarin treatments, showcasing lucrative market opportunities. Moreover, increasing awareness and the evolution of novel therapies, like gene therapies and personalized medicines, present further growth prospects. However, growth is challenged by limitations such as stringent regulatory requirements, high costs of treatment, and potential side effects related to key therapeutic regimes. In the competitive market landscape, entry by generics manufacturers post-patent expiration of key drugs also poses significant pricing challenges. Optimal innovation avenues lie in the development of safer, more effective treatment modalities with fewer side effects and the application of artificial intelligence in predicting patient-specific therapy responses. Additionally, research into the genetic basis of VTE to develop targeted treatments could propel future growth. Strategic recommendations for businesses include investing in R&D for innovative therapeutics, expanding patient education programs to enhance early detection and prevention, and forming strategic alliances to broaden market penetration. The VTE therapeutic market is dynamic, marked by evolving technologies and standards, reflecting both the complexity and potential within this healthcare sector.

KEY MARKET STATISTICS
Base Year [2023] USD 2.40 billion
Estimated Year [2024] USD 2.54 billion
Forecast Year [2030] USD 3.57 billion
CAGR (%) 5.84%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Venous Thromboembolism Therapeutic Market

The Venous Thromboembolism Therapeutic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Escalating rate of venous thromboembolism
    • Increasing surgical procedures such as hip and knee replacements
    • Increase in patient awareness towards VTE treatment
  • Market Restraints
    • High treatment cost and side effects associated with VTE drugs
  • Market Opportunities
    • Development of efficient and advanced technology
    • Government initiatives for venous thromboembolism treatments
  • Market Challenges
    • Stringent and complex regulatory procedures

Porter's Five Forces: A Strategic Tool for Navigating the Venous Thromboembolism Therapeutic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Venous Thromboembolism Therapeutic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Venous Thromboembolism Therapeutic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Venous Thromboembolism Therapeutic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Venous Thromboembolism Therapeutic Market

A detailed market share analysis in the Venous Thromboembolism Therapeutic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Venous Thromboembolism Therapeutic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Venous Thromboembolism Therapeutic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Venous Thromboembolism Therapeutic Market

A strategic analysis of the Venous Thromboembolism Therapeutic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Venous Thromboembolism Therapeutic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AngioDynamics, Inc., Argon Medical Devices, Inc., Arjo AB, Bio Compression Systems, BioInvent International AB, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Company, Cardinal Health, Inc., Cook Group Incorporated, DAIICHI SANKYO COMPANY, LIMITED, eXIthera Pharmaceuticals, Koninklijke Philips N.V., Medtronic PLC, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Venous Thromboembolism Therapeutic Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Direct Thrombin Inhibitors, Factor XA Inhibitors, Heparin, and Vitamin K Antagonists.
  • Based on Device, market is studied across Compression System, IVC Filters, Stockings, and Thrombectomy Systems.
  • Based on Application, market is studied across Deep vein Thrombosis and Pulmonary Embolism.
  • Based on End-use, market is studied across Catheterization Laboratories and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Escalating rate of venous thromboembolism
      • 5.1.1.2. Increasing surgical procedures such as hip and knee replacements
      • 5.1.1.3. Increase in patient awareness towards VTE treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment cost and side effects associated with VTE drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of efficient and advanced technology
      • 5.1.3.2. Government initiatives for venous thromboembolism treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent and complex regulatory procedures
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Venous Thromboembolism Therapeutic Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Direct Thrombin Inhibitors
  • 6.3. Factor XA Inhibitors
  • 6.4. Heparin
  • 6.5. Vitamin K Antagonists

7. Venous Thromboembolism Therapeutic Market, by Device

  • 7.1. Introduction
  • 7.2. Compression System
  • 7.3. IVC Filters
  • 7.4. Stockings
  • 7.5. Thrombectomy Systems

8. Venous Thromboembolism Therapeutic Market, by Application

  • 8.1. Introduction
  • 8.2. Deep vein Thrombosis
  • 8.3. Pulmonary Embolism

9. Venous Thromboembolism Therapeutic Market, by End-use

  • 9.1. Introduction
  • 9.2. Catheterization Laboratories
  • 9.3. Hospitals

10. Americas Venous Thromboembolism Therapeutic Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Venous Thromboembolism Therapeutic Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Venous Thromboembolism Therapeutic Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AngioDynamics, Inc.
  • 3. Argon Medical Devices, Inc.
  • 4. Arjo AB
  • 5. Bio Compression Systems
  • 6. BioInvent International AB
  • 7. Boehringer Ingelheim International GmbH
  • 8. Boston Scientific Corporation
  • 9. Bristol-Myers Squibb Company
  • 10. Cardinal Health, Inc.
  • 11. Cook Group Incorporated
  • 12. DAIICHI SANKYO COMPANY, LIMITED
  • 13. eXIthera Pharmaceuticals
  • 14. Koninklijke Philips N.V.
  • 15. Medtronic PLC
  • 16. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET RESEARCH PROCESS
  • FIGURE 2. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET DYNAMICS
  • TABLE 7. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HEPARIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COMPRESSION SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY IVC FILTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY STOCKINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THROMBECTOMY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY CATHETERIZATION LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 191. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023